Suven Life Sciences Limited (IN:SUVEN)
:SUVEN
SUVEN Stock Chart & Stats
₹165.00
₹14.56(11.52%)
At close: 4:00 PM EST
₹165.00
₹14.56(11.52%)
Day’s Range― - ―
52-Week Range₹115.00 - ₹303.00
Previous CloseN/A
Volume2.87M
Average Volume (3M)14.83K
Market Cap
₹36.51B
Enterprise Value₹36.54B
Total Cash (Recent Filing)₹2.59B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.48
Shares Outstanding231,951,810
10 Day Avg. Volume16,308
30 Day Avg. Volume14,834
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)24.25
Price to Sales (P/S)400.69
P/FCF Ratio-14.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageNear-zero debt materially lowers solvency risk and preserves financial optionality over months. With minimal interest burden the company can prioritize restructuring, R&D or selective capital raises without heavy fixed financing costs, improving survival odds while earnings recover.
Contract R&D Business ModelFee-based CRO services create durable revenue channels tied to multi-month project work and client relationships. This business model supports recurring project pipelines and long sales cycles that, if stabilized, can deliver predictable revenue streams and allow capacity planning over a 2-6 month horizon.
Specialized Medicinal-chemistry CapabilitiesProprietary skills in medicinal chemistry and discovery support are high-value, hard-to-replicate services that foster client stickiness and command technical premium. These capabilities underpin competitive differentiation and position the company to win long-term discovery mandates from pharma/biotech partners.
Bears Say
Revenue DeclineA material revenue drop signals waning demand or project loss, harming scale economics. Sustained declines reduce ability to cover fixed laboratory costs and erode bargaining power with clients, impairing prospects for margin recovery and investment in business-restoring initiatives.
Negative Gross ProfitNegative gross profit implies core services are sold below direct costs, not merely impacted by overhead. This structural unprofitability threatens the business model: unless pricing, project mix, or cost base change, continuing negative gross margins will consume capital and block sustainable operating recovery.
Persistent Cash BurnConsistent negative operating and free cash flow creates an urgent funding need and reduces strategic flexibility. Over a multi-month horizon persistent cash burn raises the likelihood of external financing, asset sales, or downsizing, which can disrupt R&D delivery and client relationships.
Suven Life Sciences Limited News
SUVEN FAQ
What was Suven Life Sciences Limited’s price range in the past 12 months?
Suven Life Sciences Limited lowest stock price was ₹115.00 and its highest was ₹303.00 in the past 12 months.
What is Suven Life Sciences Limited’s market cap?
Suven Life Sciences Limited’s market cap is ₹36.51B.
When is Suven Life Sciences Limited’s upcoming earnings report date?
Suven Life Sciences Limited’s upcoming earnings report date is Apr 30, 2026 which is in 25 days.
How were Suven Life Sciences Limited’s earnings last quarter?
Suven Life Sciences Limited released its earnings results on Jan 29, 2026. The company reported -₹4.481 earnings per share for the quarter, missing the consensus estimate of N/A by -₹4.481.
Is Suven Life Sciences Limited overvalued?
According to Wall Street analysts Suven Life Sciences Limited’s price is currently Overvalued.
Does Suven Life Sciences Limited pay dividends?
Suven Life Sciences Limited pays a Annually dividend of ₹1.382 which represents an annual dividend yield of N/A. See more information on Suven Life Sciences Limited dividends here
What is Suven Life Sciences Limited’s EPS estimate?
Suven Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Suven Life Sciences Limited have?
Suven Life Sciences Limited has 231,951,810 shares outstanding.
What happened to Suven Life Sciences Limited’s price movement after its last earnings report?
Suven Life Sciences Limited reported an EPS of -₹4.481 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.758%.
Which hedge fund is a major shareholder of Suven Life Sciences Limited?
Currently, no hedge funds are holding shares in IN:SUVEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Suven Life Sciences Limited
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities (NCEs) in central nervous system therapies. Its product candidates include SUVN-502 for the treatment of Alzheimer's disease and neuropsychiatric symptoms; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. The company is also developing SUVN-D4010, a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders and schizophrenia; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.
Technical Analysis
Aarti Drugs Limited
―
Gufic Biosciences Limited
―
―
Sun Pharma Advanced Research Co. Ltd.
―
Supriya Lifescience Limited
―